Just two months after the FDA accepted for review Teva’s long-acting version of a decades-old schizophrenia drug, the Israeli pharma is launching a community project to help people with the disorder and their carers.
New AI tools could screen existing CT scans to asses risk for heart disease. But, who'll pay for it, and will it improve health outcomes?
“These sides aren't talking to each other. And there's a lot riding on it”: the podcast trying to bridge MAHA and public health.
A surprising discovery from high-altitude animals like yaks and Tibetan antelopes could reshape how we treat nerve damage in humans. Scientists found that a genetic mutation helping these animals survive low-oxygen environments also protects and repairs the myelin sheath—the vital coating around nerve fibers that’s damaged in diseases like multiple sclerosis (MS) and cerebral paralysis.
Drug names are complicated things. For one, they must linguistically fulfill the role of being a shiny bauble for prescribers to be memorable enough to outshine competitors. But there’s much more than just surface-level appeal at play.
A lifetime of mental stimulation—like reading, writing, and learning new skills—may help protect the brain as we age. People with the highest levels of cognitive enrichment had a much lower risk of Alzheimer’s and experienced symptoms years later than those with the lowest levels.
Scientists have taken a major step toward stopping Epstein-Barr virus (EBV), an extremely common infection linked to cancer and chronic disease. By using mice engineered with human antibody genes, researchers created powerful human-like antibodies that block the virus from attaching to and entering immune cells. One of these antibodies completely prevented infection in lab models with human immune
A major new study reveals that treating gout may do far more than ease painful joint flare-ups—it could also protect the heart. Researchers found that patients who took common gout medications like allopurinol and successfully lowered their blood urate levels had a significantly reduced risk of heart attacks, strokes, and cardiovascular death over five years.
Travere is eyeing a collective $3 billion U.S. opportunity for Filspari thanks to a new rare kidney disease nod, plus the med's initial 2023 approval in another rare kidney indication.
The key health care issues we're watching as Congress returns from recess.
Even as Eli Lilly gets underway with its next major obesity launch in Foundayo, the FDA's approval letter for the oral treatment shows lingering reservations about multiple "unexpected serious" risks potentially related to the drug.
Ben Sasse on enrolling in Rev Med's drug trial, more ADC investment, and other biotech news from The Readout
In this edition of STAT Health Tech: Hospitals offer their own chatbots, Medicare's ACCESS pilot, and an update Utah's 'AI doctor' experiment.
Protagonist Therapeutics-partnered Icotyde has the potential to become one of Johnson & Johnson's "largest products ever," CEO Joaquin Duato said on the company's first-quarter earnings conference call.
The AI will be used to analyze complex datasets and shrink R&D timelines, Novo said. It'll additionally use the tech to seek efficiencies across manufacturing and corporate functions.
Bread and other carbohydrate staples may be doing more than just filling plates—they could be quietly reshaping metabolism. In a surprising twist, researchers found that mice strongly preferred carbs like bread, rice, and wheat, abandoning their regular diet entirely. Even without eating more calories, they gained weight and body fat, not because they overate, but because their bodies burned less
Scientists have discovered a way to supercharge the immune system’s T cells by blocking a protein called Ant2, forcing the cells to rewire how they generate energy. This shift makes them more powerful, resilient, and effective at finding and destroying cancer cells.
The director of WHO's Eastern Mediterranean region is weighing whether to run to be the next director-general at a time of tumult over Iran and beyond.
Former Sen. Ben Sasse gives a glimpse of what it's like to be a participant in an tough but promising new drug for pancreatic cancer.
Dana-Farber CEO Benjamin Ebert has no shortage of ideas and vision for the cancer institute as it untangles from Mass General Brigham and builds a new hospital.